O42254
Gene name |
IGF2BP1 (VICKZ1, ZBP1) |
Protein name |
Insulin-like growth factor 2 mRNA-binding protein 1 |
Names |
IGF2 mRNA-binding protein 1, IMP-1, IGF-II mRNA-binding protein 1, VICKZ family member 1, Zip-code binding polypeptide, Zipcode-binding protein 1, ZBP-1 |
Species |
Gallus gallus (Chicken) |
KEGG Pathway |
gga:395953 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
4 structures for O42254
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2N8L | NMR | - | A | 387-573 | PDB |
| 2N8M | NMR | - | A | 387-573 | PDB |
| 8COO | NMR | - | A | 387-573 | PDB |
| AF-O42254-F1 | Predicted | AlphaFoldDB |
No variants for O42254
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for O42254 | |||||
No associated diseases with O42254
12 regional properties for O42254
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | RNA recognition motif domain | 2 - 75 | IPR000504-1 |
| domain | RNA recognition motif domain | 81 - 156 | IPR000504-2 |
| domain | K Homology domain | 194 - 265 | IPR004087-1 |
| domain | K Homology domain | 275 - 348 | IPR004087-2 |
| domain | K Homology domain | 403 - 474 | IPR004087-3 |
| domain | K Homology domain | 485 - 557 | IPR004087-4 |
| domain | K Homology domain, type 1 | 198 - 262 | IPR004088-1 |
| domain | K Homology domain, type 1 | 280 - 344 | IPR004088-2 |
| domain | K Homology domain, type 1 | 406 - 470 | IPR004088-3 |
| domain | K Homology domain, type 1 | 489 - 553 | IPR004088-4 |
| domain | IGF2BP1, RNA recognition motif 1 | 1 - 77 | IPR034837 |
| domain | IGF2BP1, RNA recognition motif 2 | 81 - 156 | IPR034842 |
Functions
10 GO annotations of cellular component
| Name | Definition |
|---|---|
| CRD-mediated mRNA stability complex | A protein complex that binds to, and promotes stabilization of, mRNA molecules containing the coding region instability determinant (CRD). In human, it may consist of IGF2BP1, HNRNPU, SYNCRIP/HNRNPQ, YBX1, and DHX9. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoplasmic stress granule | A dense aggregation in the cytosol composed of proteins and RNAs that appear when the cell is under stress. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| filopodium | Thin, stiff, actin-based protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal or dendritic growth cone, or a dendritic shaft. |
| growth cone | The migrating motile tip of a growing neuron projection, where actin accumulates, and the actin cytoskeleton is the most dynamic. |
| lamellipodium | A thin sheetlike process extended by the leading edge of a migrating cell or extending cell process; contains a dense meshwork of actin filaments. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| P-body | A focus in the cytoplasm where mRNAs may become inactivated by decapping or some other mechanism. Protein and RNA localized to these foci are involved in mRNA degradation, nonsense-mediated mRNA decay (NMD), translational repression, and RNA-mediated gene silencing. |
| perinuclear region of cytoplasm | Cytoplasm situated near, or occurring around, the nucleus. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| mRNA 3'-UTR binding | Binding to a 3' untranslated region of an mRNA molecule. |
| mRNA binding | Binding to messenger RNA (mRNA), an intermediate molecule between DNA and protein. mRNA includes UTR and coding sequences, but does not contain introns. |
| N6-methyladenosine-containing RNA binding | Binding to an RNA molecule modified by N6-methyladenosine (m6A), a modification present at internal sites of mRNAs and some non-coding RNAs. |
7 GO annotations of biological process
| Name | Definition |
|---|---|
| CRD-mediated mRNA stabilization | An mRNA stabilization process in which one or more RNA-binding proteins associate with a sequence in the open reading frame called the coding region instability determinant (CRD). |
| mRNA transport | The directed movement of mRNA, messenger ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of translation | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. |
| nervous system development | The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state. |
| positive regulation of neuron projection development | Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
| regulation of gene expression | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| regulation of RNA metabolic process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving RNA. |
9 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q5ZLP8 | IGF2BP3 | Insulin-like growth factor 2 mRNA-binding protein 3 | Gallus gallus (Chicken) | PR |
| O00425 | IGF2BP3 | Insulin-like growth factor 2 mRNA-binding protein 3 | Homo sapiens (Human) | PR |
| Q9Y6M1 | IGF2BP2 | Insulin-like growth factor 2 mRNA-binding protein 2 | Homo sapiens (Human) | PR |
| Q9NZI8 | IGF2BP1 | Insulin-like growth factor 2 mRNA-binding protein 1 | Homo sapiens (Human) | PR |
| Q5SF07 | Igf2bp2 | Insulin-like growth factor 2 mRNA-binding protein 2 | Mus musculus (Mouse) | PR |
| Q9CPN8 | Igf2bp3 | Insulin-like growth factor 2 mRNA-binding protein 3 | Mus musculus (Mouse) | PR |
| O88477 | Igf2bp1 | Insulin-like growth factor 2 mRNA-binding protein 1 | Mus musculus (Mouse) | PR |
| Q8CGX0 | Igf2bp1 | Insulin-like growth factor 2 mRNA-binding protein 1 | Rattus norvegicus (Rat) | PR |
| Q08CK7 | igf2bp1 | Insulin-like growth factor 2 mRNA-binding protein 1 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MNKLYIGNLN | ESVTPADLEK | VFNDHKISFS | GQFLVKSGYA | FVDCPDEQWA | MKAIETFSGK |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VELHGKQLEI | EHSVPKKQRS | RKIQIRNIPP | QLRWEVLDGL | LAQYGTVENC | EQVNTDSETA |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VVNVTYTNRE | QTRQAIMKLN | GHQLENHVLK | VSYIPDEQSV | QGPENGRRGG | FGARGAPRQG |
| 190 | 200 | 210 | 220 | 230 | 240 |
| SPVTAGAPVK | QQPVDIPLRL | LVPTQYVGAI | IGKEGATIRN | ITKQTQSKID | VHRKENAGAA |
| 250 | 260 | 270 | 280 | 290 | 300 |
| EKAISIHSTP | EGCSAACKMI | LEIMQKEAKD | TKTADEVPLK | ILAHNNFVGR | LIGKEGRNLK |
| 310 | 320 | 330 | 340 | 350 | 360 |
| KVEQDTETKI | TISSLQDLTL | YNPERTITVK | GSIENCCKAE | QEIMKKVREA | YENDVAAMSL |
| 370 | 380 | 390 | 400 | 410 | 420 |
| QSHLIPGLNL | AAVGLFPASS | NAVPPPPSSV | SGAAPYSSFM | PPEQETVHVF | IPAQAVGAII |
| 430 | 440 | 450 | 460 | 470 | 480 |
| GKKGQHIKQL | SRFASASIKI | APPETPDSKV | RMVVITGPPE | AQFKAQGRIY | GKLKEENFFG |
| 490 | 500 | 510 | 520 | 530 | 540 |
| PKEEVKLETH | IRVPASAAGR | VIGKGGKTVN | ELQNLTAAEV | VVPRDQTPDE | NEQVIVKIIG |
| 550 | 560 | 570 | |||
| HFYASQMAQR | KIRDILAQVK | QQHQKGQSGQ | LQARRK |